Daniel Hamaoui

Founder & CEO

Daniel earned his PhD at INSERM where he worked with microbial toxins as tools to activate specific components in cells. After working at the Institut Pasteur in Paris he joined the entrepreneurial Shaker program at the Genopole as a project leader.

He developed the Self-Entering CRISPR Cas proteins and the Self-Entering single-chain antibodies before founding SE Therapeutics.

Anthony Yasmann

Co-founder & CSO

Anthony has over a decade of experience as an interdisciplinary experimental scientist. Most recently he was charged with developing monoclonal antibodies at Memorial Sloan Kettering Cancer Center.

He earned his doctorate at the Institut Pasteur working on skeletal muscle regeneration and serotonin signaling. Anthony contributes to the scientific missions and business development of SE Therapeutics.

Erwan Bézard

KOL in neurological disorders – Expert Shareholder

Erwan is recognized worldwide for his expertise in Gene and Cell therapy in the brain. He heads a multidisciplinary team at the “Institut des maladies neurodegenratives” in Bordeaux. He complements his renowned academic accomplishments with an entrepreneurial mindset.

He is involved in multiple startups such as Treefrog therapeutics and is the CSO of motac Neuroscience. 

Jean-Christophe Rain

Business strategy – Expert Shareholder

Jean-Christophe is our business and scientific strategy advisor. He is the CEO of Hybrigenics Services and is involved with multiple projects and startups. His experience and insight are helping us structure our business development plans.

Agathe Subtil

R&D specialist – Expert shareholder

Agathe is a Principal Investigator at the Pasteur Institute who graduated from the prestigious Ecole Normale Supérieure.

She is an accomplished scientist with a vast network in Europe and the US. She advises us with our R&D program as well as establishing contact with various experts in the biomedical field.